Association between tumor necrosis factor in serum and cachexia in patients with prostate cancer

Jun Nakashima, Masaaki Tachibana, Munehisa Ueno, Akira Miyajima, Shiro Baba, Masaru Murai

Research output: Contribution to journalArticle

102 Citations (Scopus)

Abstract

The present study was undertaken to evaluate the relationship between serum tumor necrosis factor (TNF) and cachexia in patients with prostate cancer. TNF levels were determined in 110 serum samples from prostate cancer patients by an enzyme immunoassay. Serum TNF activity was positive in 76% of the patients with relapsed disease, whereas only 11% of the untreated patients and 0% of the patients in remission as a result of endocrine therapy were positive. The serum total protein and albumin levels, hemoglobin levels, and body mass index of the patients with elevated serum TNF levels were significantly lower (P < 0.05) than the corresponding values in patients with undetectable serum TNF levels. The serum TNF levels of patients with serum albumin levels of <3.5 g/dl, serum total protein levels of <7.0 g/dl, hemoglobin levels of <11.0 g/dl, and a body mass index of <21 kg/m2 were significantly higher (P < 0.05) than the values in their respective counterparts. There was a significant correlation between the detectability of serum TNF and performance status (P < 0.05). Patients with elevated serum TNF levels had a significantly higher mortality rate (P < 0.05) than those with undetectable serum TNF levels. These findings suggest that TNF may be one of the factors contributing to the complex syndrome of cachexia in patients with prostate cancer.

Original languageEnglish
Pages (from-to)1743-1748
Number of pages6
JournalClinical Cancer Research
Volume4
Issue number7
Publication statusPublished - 1998 Jul

Fingerprint

Cachexia
Prostatic Neoplasms
Tumor Necrosis Factor-alpha
Serum
Serum Albumin
Blood Proteins
Hemoglobins
Body Mass Index
Immunoenzyme Techniques

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Nakashima, J., Tachibana, M., Ueno, M., Miyajima, A., Baba, S., & Murai, M. (1998). Association between tumor necrosis factor in serum and cachexia in patients with prostate cancer. Clinical Cancer Research, 4(7), 1743-1748.

Association between tumor necrosis factor in serum and cachexia in patients with prostate cancer. / Nakashima, Jun; Tachibana, Masaaki; Ueno, Munehisa; Miyajima, Akira; Baba, Shiro; Murai, Masaru.

In: Clinical Cancer Research, Vol. 4, No. 7, 07.1998, p. 1743-1748.

Research output: Contribution to journalArticle

Nakashima, J, Tachibana, M, Ueno, M, Miyajima, A, Baba, S & Murai, M 1998, 'Association between tumor necrosis factor in serum and cachexia in patients with prostate cancer', Clinical Cancer Research, vol. 4, no. 7, pp. 1743-1748.
Nakashima J, Tachibana M, Ueno M, Miyajima A, Baba S, Murai M. Association between tumor necrosis factor in serum and cachexia in patients with prostate cancer. Clinical Cancer Research. 1998 Jul;4(7):1743-1748.
Nakashima, Jun ; Tachibana, Masaaki ; Ueno, Munehisa ; Miyajima, Akira ; Baba, Shiro ; Murai, Masaru. / Association between tumor necrosis factor in serum and cachexia in patients with prostate cancer. In: Clinical Cancer Research. 1998 ; Vol. 4, No. 7. pp. 1743-1748.
@article{8b0a498cf64e4e5a8b53f33956708901,
title = "Association between tumor necrosis factor in serum and cachexia in patients with prostate cancer",
abstract = "The present study was undertaken to evaluate the relationship between serum tumor necrosis factor (TNF) and cachexia in patients with prostate cancer. TNF levels were determined in 110 serum samples from prostate cancer patients by an enzyme immunoassay. Serum TNF activity was positive in 76{\%} of the patients with relapsed disease, whereas only 11{\%} of the untreated patients and 0{\%} of the patients in remission as a result of endocrine therapy were positive. The serum total protein and albumin levels, hemoglobin levels, and body mass index of the patients with elevated serum TNF levels were significantly lower (P < 0.05) than the corresponding values in patients with undetectable serum TNF levels. The serum TNF levels of patients with serum albumin levels of <3.5 g/dl, serum total protein levels of <7.0 g/dl, hemoglobin levels of <11.0 g/dl, and a body mass index of <21 kg/m2 were significantly higher (P < 0.05) than the values in their respective counterparts. There was a significant correlation between the detectability of serum TNF and performance status (P < 0.05). Patients with elevated serum TNF levels had a significantly higher mortality rate (P < 0.05) than those with undetectable serum TNF levels. These findings suggest that TNF may be one of the factors contributing to the complex syndrome of cachexia in patients with prostate cancer.",
author = "Jun Nakashima and Masaaki Tachibana and Munehisa Ueno and Akira Miyajima and Shiro Baba and Masaru Murai",
year = "1998",
month = "7",
language = "English",
volume = "4",
pages = "1743--1748",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Association between tumor necrosis factor in serum and cachexia in patients with prostate cancer

AU - Nakashima, Jun

AU - Tachibana, Masaaki

AU - Ueno, Munehisa

AU - Miyajima, Akira

AU - Baba, Shiro

AU - Murai, Masaru

PY - 1998/7

Y1 - 1998/7

N2 - The present study was undertaken to evaluate the relationship between serum tumor necrosis factor (TNF) and cachexia in patients with prostate cancer. TNF levels were determined in 110 serum samples from prostate cancer patients by an enzyme immunoassay. Serum TNF activity was positive in 76% of the patients with relapsed disease, whereas only 11% of the untreated patients and 0% of the patients in remission as a result of endocrine therapy were positive. The serum total protein and albumin levels, hemoglobin levels, and body mass index of the patients with elevated serum TNF levels were significantly lower (P < 0.05) than the corresponding values in patients with undetectable serum TNF levels. The serum TNF levels of patients with serum albumin levels of <3.5 g/dl, serum total protein levels of <7.0 g/dl, hemoglobin levels of <11.0 g/dl, and a body mass index of <21 kg/m2 were significantly higher (P < 0.05) than the values in their respective counterparts. There was a significant correlation between the detectability of serum TNF and performance status (P < 0.05). Patients with elevated serum TNF levels had a significantly higher mortality rate (P < 0.05) than those with undetectable serum TNF levels. These findings suggest that TNF may be one of the factors contributing to the complex syndrome of cachexia in patients with prostate cancer.

AB - The present study was undertaken to evaluate the relationship between serum tumor necrosis factor (TNF) and cachexia in patients with prostate cancer. TNF levels were determined in 110 serum samples from prostate cancer patients by an enzyme immunoassay. Serum TNF activity was positive in 76% of the patients with relapsed disease, whereas only 11% of the untreated patients and 0% of the patients in remission as a result of endocrine therapy were positive. The serum total protein and albumin levels, hemoglobin levels, and body mass index of the patients with elevated serum TNF levels were significantly lower (P < 0.05) than the corresponding values in patients with undetectable serum TNF levels. The serum TNF levels of patients with serum albumin levels of <3.5 g/dl, serum total protein levels of <7.0 g/dl, hemoglobin levels of <11.0 g/dl, and a body mass index of <21 kg/m2 were significantly higher (P < 0.05) than the values in their respective counterparts. There was a significant correlation between the detectability of serum TNF and performance status (P < 0.05). Patients with elevated serum TNF levels had a significantly higher mortality rate (P < 0.05) than those with undetectable serum TNF levels. These findings suggest that TNF may be one of the factors contributing to the complex syndrome of cachexia in patients with prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=0031746794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031746794&partnerID=8YFLogxK

M3 - Article

C2 - 9676850

AN - SCOPUS:0031746794

VL - 4

SP - 1743

EP - 1748

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 7

ER -